Similarly, pioneering in melanoma is the interest in the development of a new “alarmin‐based” vaccine, biotherapeutic, and phytotherapeutic strategies exploiting the immunoinductive, antiproliferative, and the cell‐killing potential that has emerged for HMGN1, hBD‐1, hBD‐2, and plant‐derived defensins. Here, DEFB1 is linked to melanoma.